Abstract
Microvascular complications associated with type 1 diabetes mellitus (T1DM) are caused in part by endothelial dysfunction. We aimed to determine the association between polymorphisms in endothelial nitric oxide synthase (eNOS) gene (894G>T, 4ab) and T1DM-associated microvascular disorders, and the roles of nitrite/nitrate products (NOx) and low molecular weight-AGEs (LMW-AGEs) levels in this relationship. We carried out a case-control study (328 subjects) and determined genotypes by PCR. The rare-type TT of eNOS 894G>T was significantly overrepresented in patients without microvascular disorders as compared with control (OR=3.64; 95% C.I.=1.02–12.73; P=0.039). The prevalence of neuropathy was high among 894GG homozygotes (OR=0.5; 95% C.I.=0.29–0.86; P=0.012) who had high levels of triglycerides, elevated systolic BP, increased NOx, and LMW-AGEs. Decreased NOx levels were associated with 894TT genotype (beta=−0.65; P=0.043) in diabetic patients prone to microvascular complications. Multiple regression analysis indicated a negative correlation between eNOS 894G>T and diabetic neuropathy (P=0.025). The distribution of eNOS 4aa genotype was high (P=0.042) in patients with T1DM; however, it does not represent a risk factor for neuropathy. The overrepresentation of eNOS 894TT genotype in diabetic patients is associated with low risk for neuropathy. Decreased NOx and LMW-AGEs levels and lower lipid profile are the main features of patients carrying the eNOS 894T allele. These data suggest that the eNOS 894TT genotype may play a protective role by preventing microvascular disorders.
[1] Costacou T., Chang Y., Ferrell R.E., Orchard T.J., Identifying genetic susceptibilities to diabetesrelated complications among individuals at low risk of complications: An application of tree-structured survival analysis, Am. J. Epidemiol., 2006, 164, 862–872 http://dx.doi.org/10.1093/aje/kwj28710.1093/aje/kwj287Search in Google Scholar
[2] Taverna M.J., Sola A., Guyot-Argenton C., Pacher N., Bruzzo F., Chevalier A., et al., eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy, Diabet. Med., 2002, 19, 240–245 http://dx.doi.org/10.1046/j.1464-5491.2002.00681.x10.1046/j.1464-5491.2002.00681.xSearch in Google Scholar
[3] Taverna M.J., Elgrably F., Selmi H., Selam J.L., Slama G., The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy, Nitric Oxide, 2005, 13, 88–92 http://dx.doi.org/10.1016/j.niox.2005.04.00410.1016/j.niox.2005.04.004Search in Google Scholar
[4] Zanchi A., Moczulski D.K., Hanna L.S., Wantman M., Warram J.H., Krolewski A.S., Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism, Kidney Int., 2000, 57, 405–413 http://dx.doi.org/10.1046/j.1523-1755.2000.00860.x10.1046/j.1523-1755.2000.00860.xSearch in Google Scholar
[5] Chiarelli F., Cipollone F., Romano F., Tumini S., Costantini F., di Ricco L., et al., Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration, Diabetes, 2000, 49, 1258–1263 http://dx.doi.org/10.2337/diabetes.49.7.125810.2337/diabetes.49.7.1258Search in Google Scholar
[6] Sharp P.S., Rainbow S., Mukherjee S., Serum levels of low molecular weight advanced glycation end products in diabetic subjects, Diabet. Med., 2003, 20, 575–579 http://dx.doi.org/10.1046/j.1464-5491.2003.00973.x10.1046/j.1464-5491.2003.00973.xSearch in Google Scholar
[7] Moncada S., Higgs E.A., Molecular mechanisms and therapeutic strategies related to nitric oxide, FASEB J., 1995, 9, 1319–1330 10.1096/fasebj.9.13.7557022Search in Google Scholar
[8] Zochodne D.W., Levy D., Nitric oxide in damage, disease and repair of the peripheral nervous system, Cell. Mol. Biol. (Noisy-le-grand), 2005, 51, 255–267 Search in Google Scholar
[9] Heltianu C., Manea S.A., Guja C., Mihai C., Ionescu-Tirgoviste C., Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients, Cent. Eur. J. Biol., 2008, 3, 243–249 http://dx.doi.org/10.2478/s11535-008-0019-410.2478/s11535-008-0019-4Search in Google Scholar
[10] Green A., Gale E.A., Patterson C.C., Incidence of childhood onset insulin-dependent diabetes mellitus: the EURODIAB ACE Study, Lancet, 1992, 339, 905–909 http://dx.doi.org/10.1016/0140-6736(92)90938-Y10.1016/0140-6736(92)90938-YSearch in Google Scholar
[11] Guja C., Ionescu-Tirgoviste C., Chronic angiopathic complications in type 1 diabetes across Europe as a result of EURODIAB multicentric study, In: Simionescu M., Sima A., Popov D., (Eds), Cellular dysfunction in atherosclerosis and diabetes-reports from bench to bedside, Romanian Academy Publishing House, Bucharest, 2004, 408–421 Search in Google Scholar
[12] Heltianu C., Costache G., Azibi K., Poenaru L., Simionescu M., Endothelial nitric oxide synthase gene polymorphism in Fabry’s disease, Clin. Genet., 2002, 61, 423–429 http://dx.doi.org/10.1034/j.1399-0004.2002.610605.x10.1034/j.1399-0004.2002.610605.xSearch in Google Scholar PubMed
[13] Tsukada T., Yokoyama K., Arai T., Takemoto F., Hara S., Yamada A., et al., Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans, Biochem. Biophys. Res. Comm., 1998, 245, 190–193 http://dx.doi.org/10.1006/bbrc.1998.826710.1006/bbrc.1998.8267Search in Google Scholar PubMed
[14] Ahsan A., Mohd G., Norboo T., Baig M.A., Pasha M.A., Heterozygotes of NOS3 polymorphisms contribute to reduced nitrogen oxides in high-altitude pulmonary edema, Chest, 2006, 130, 1511–1519 http://dx.doi.org/10.1378/chest.130.5.151110.1378/chest.130.5.1511Search in Google Scholar PubMed
[15] Pereira E.C., Ferderbar S., Bertolami M.C., Faludi A.A., Monte O., Xavier H.T., et al., Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus, Clin. Biochem., 2008, 41, 1454–1460 http://dx.doi.org/10.1016/j.clinbiochem.2008.08.07410.1016/j.clinbiochem.2008.08.074Search in Google Scholar PubMed
[16] Choi K.C., Kim N.H., An M.R., Kang D.G., Kim S.W., Lee J., Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats, Kidney Int., 1997, Suppl. 60, 23–27 Search in Google Scholar
[17] Cameron N.E., Eaton S.E., Cotter M.A., Tesfaye S., Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy, Diabetologia, 2001, 44, 1973–1988 http://dx.doi.org/10.1007/s00125010000110.1007/s001250100001Search in Google Scholar PubMed
[18] Beleslin-Cokic B.B., Cokic V.P., Yu X., Weksler B.B., Schechter A.N., Noguchi C.T., Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells, Blood, 2004, 104, 2073–2080 http://dx.doi.org/10.1182/blood-2004-02-074410.1182/blood-2004-02-0744Search in Google Scholar PubMed
© 2009 Versita Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
